Scientific deep-dive

Tirzepatide Week by Week: What the SURMOUNT Trials Recorded

The dose ladder takes months, not weeks. This sets out what SURMOUNT-1, 2 and 4 recorded at each stage on Zepbound and Mounjaro, and the roughly half of the lost weight that came back when people stopped.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·4 citations

Tirzepatide climbs a longer ladder than most people are told. The label starts at 2.5 mg and raises the dose no faster than every four weeks, so reaching the top of the range takes months, not weeks. In SURMOUNT-4, the trial built to test what continuing is worth, participants spent 36 weeks in open-label treatment before the real experiment started, losing about 20.9% along the way.[3] Here is what each SURMOUNT trial recorded, and what happened to the people who stopped.

The ladder comes first

Zepbound and Mounjaro both begin at 2.5 mg once weekly, and that opening dose is there to be tolerated rather than to work. Zepbound’s label is explicit that 2.5 mg is a starting dose only, with no approval as a dose to stay on. After four weeks the dose goes to 5 mg, and from there it can rise in 2.5 mg steps, each after at least four weeks on the current dose.[4] Zepbound and Mounjaro come in the same six strengths, from 2.5 mg to 15 mg; how much each maintenance dose delivered in the trials is set out in which Zepbound dose works best.

The practical consequence is that anyone measuring their progress in the first month or two is measuring the ladder, not the drug at its working dose. Our titration planner lays the schedule out against real dates from each label, and the Zepbound pen chart covers which strength is which.

If you buy compounded tirzepatide, the ladder can also have a price attached. BioGlow Health and GetRelief Rx charge more as the dose rises, and GetRelief sells only a daily under-the-tongue form, not a weekly injection. NoBsRx charges the same at any dose. StaveMD runs its plans on a four-week renewal, the same interval as each step on the label, while Novera MD shows the plan length behind its advertised figure only after a long intake.

Alan Meds also keeps one price at every dose, but the injectable compounded tirzepatide it lists is priced on a six-month plan paid up front. That is a long prepayment to weigh against a ladder whose upper steps you have not tried yet.

What 72 weeks produced

SURMOUNT-1 is the trial the rest are measured against. It enrolled 2,539 adults living with obesity and without diabetes and tested three doses (5, 10 and 15 mg) against placebo over 72 weeks. The top dose finished at −20.9% against −3.1% on placebo, and roughly 57% of that arm lost a fifth or more of their starting weight.[1]

That last figure deserves a closer look. More than half of the 15 mg arm reached a 20% loss or better, which also means a substantial minority did not, and some lost considerably less than the average. The mean describes a group and cannot predict one person’s result.

The SURMOUNT trials, what each asked, and what it found. Every figure is a group mean.
TrialPopulationDurationResult
SURMOUNT-1[1]2,539 adults with obesity, without diabetes72 weeks−20.9% at 15 mg vs −3.1% placebo; ~57% lost ≥20%
SURMOUNT-2[2]938 adults with obesity and type 2 diabetes72 weeks−14.7% at 15 mg and −12.8% at 10 mg vs −3.2%; A1C down about 2.1 points
SURMOUNT-4[3]670 people who had already lost about 20.9%36-week run-in, then 52 weeksContinuers lost a further 5.5%; those switched to placebo gained 14.0% from their week-36 weight, ending 9.9% below where they started

Diabetes changes the number

SURMOUNT-2 ran the same drug in people who had both excess weight and type 2 diabetes, and this is the population where GLP-1 drugs reliably underperform. Tirzepatide managed −14.7% at 15 mg and −12.8% at 10 mg against −3.2% on placebo, with A1C falling about 2.1 points.[2]

So roughly two-thirds to three-quarters of the effect seen without diabetes survives. If you have type 2 diabetes and have been comparing yourself against the 20.9% headline, you have been comparing yourself against the wrong trial.

What stopping did

SURMOUNT-4 is the clearest evidence on this question that exists for any GLP-1. Everyone in it first took tirzepatide openly for 36 weeks and lost about 20.9%. Then they were randomized: half continued, half moved to placebo, and both were followed for another year.

The continuers lost a further 5.5%. Those switched to placebo gained 14.0% of their week-36 weight. Measured from where everyone started, the placebo group ended the trial 9.9% lighter, against 25.3% for those who stayed on the drug.[3] By that arithmetic, about half of a 20.9% loss came back within a year, in people who had done everything the protocol asked of them. The paper itself calls it “substantial regain of lost weight.”

About half of a 20.9% loss came back within a year of switching to placebo.
Weigh this before the first injection. For most people the open question is whether they can keep getting the drug, which makes supply and cost part of the clinical picture. We keep a dated figure for every seller on the price tracker, and what happens when you stop a GLP-1 covers the physiology.

Why this is not a race against semaglutide

It is tempting to set −20.9% beside semaglutide’s −14.9% and call it settled. That comparison is not available from these trials. SURMOUNT-1 and STEP 1 enrolled different people, ran for different lengths (72 weeks against 68), and each had its own placebo arm. Reading across two separate trials as though they were arms of one is the same move we criticize when a seller makes it.

A real head-to-head does exist. SURMOUNT-5 randomized 751 people between the two drugs, each at its own maximum tolerated dose, and tirzepatide produced 20.2% against 13.7% (see the head-to-head, and what it settles). Our semaglutide timeline sets out that drug’s own record on its own terms.

What this timeline cannot tell you

  • Every figure is a group mean. Individuals scattered widely around each one, in both directions.
  • Trial conditions are not ordinary conditions. Participants had free medication, structured support and regular contact with a study team.
  • It describes the brand product at labeled doses. A compounded vial raises separate questions, taken up in is compounded tirzepatide safe.
  • It says nothing about who should take it. That is a clinical judgment about your own history.

The support gap is one you can partly close yourself. Vaylen includes check-ins and safety labs in every plan, and Fitness RX lists labs, unlimited provider visits, coaching and nutrition support in its price, on a three-month minimum. Framework includes dietitian support, though it prices no plan, drug or dose before the health questions. Ivim Health sells compounded tirzepatide from $117 a month on a 12-month program, plus a $75 monthly program fee that covers unlimited provider visits and functional health coaches. None of that recreates a trial, but it is closer than a prescription with no follow-up.

One thing the published record does not settle: how much of the 36-week run-in loss in SURMOUNT-4 came from the dose ladder versus the maintenance dose that followed it. The trial reports the total, not the split, so the shape of that first stretch is less well described for tirzepatide than for semaglutide.

Frequently Asked Questions

Weight comes off during the dose climb, but the top of the range is months away because increases come no faster than every four weeks. In SURMOUNT-4 participants lost about 20.9% across 36 weeks of open-label treatment before the trial's real experiment began.
In SURMOUNT-1 the 15 mg arm averaged a 20.9% loss over 72 weeks against 3.1% on placebo, and roughly 57% of that arm lost at least a fifth of their starting weight. That also means a substantial minority did not, and the average describes a group; it does not forecast one person’s result.
The trials show a smaller figure. SURMOUNT-2, which enrolled adults who had both obesity and type 2 diabetes, recorded 14.7% at 15 mg and 12.8% at 10 mg against 3.2% on placebo, with A1C falling about 2.1 points. Comparing yourself against the 20.9% headline from SURMOUNT-1 means comparing yourself against a different population.
About half of the lost weight returned within a year in SURMOUNT-4, the trial built to test this. People who had lost about 20.9% and were then switched to placebo gained 14.0% of their week-36 weight, ending 9.9% below their starting weight. Those who continued lost a further 5.5%, ending 25.3% below it.
SURMOUNT-1 and STEP 1 cannot answer that. They enrolled different people, ran for different lengths and each had its own placebo arm, so setting their headline numbers side by side is not a comparison. Only a head-to-head trial settles it.

References

  1. 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine. 2022. PMID: 35658024.
  2. 2.Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet. 2023. PMID: 37385275.
  3. 3.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. 2024. PMID: 38078870.
  4. 4.Eli Lilly and Company ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 2.1 dose escalation and Section 3 dosage forms and strengths DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.

6 min read

Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted

No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.

8 min read

GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning

Three of six GLP-1 labels warn about the contraceptive pill. Mounjaro and Zepbound set a four-week window after starting and after every dose increase, and Foundayo a 30-day one; the three semaglutide labels carry no such advisory. We read all six.

9 min read

Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip

Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.

7 min read

Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter

Every GLP-1 raises resting heart rate by a few beats a minute, but only Wegovy and Saxenda warn about it. What the labels show, why it happens, whether it matters, and the palpitations that point elsewhere.

9 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $69/mo + membership

Get started →
Read full review →
7.4

Wellorithm

7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →